SCHEMBL10112293

SCHEMBL10112293

CC1Oc2cccnc2-c2ccc(Br)cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TNF P01375 1/20 0.37
CYP1A2 P05177 1/20 0.35
CYP2C19 P33261 1/20 0.35
HTT P42858 1/20 0.35
PTAFR P25105 1/20 0.33
PBRM1 Q86U86 1/20 0.33
AAK1 Q2M2I8 1/20 0.32
TDP2 O95551 1/20 0.32
NSD2 O96028 1/20 0.32
ABL1 P00519 1/20 0.32
PLCG1 P19174 1/20 0.32
CES1 P23141 1/20 0.32
PAX8 Q06710 1/20 0.32
RIN1 Q13671 1/20 0.32
GAA P10253 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31474084 0.72 AAK1 (0.53) AAK1ROCK2ROCK1
SCHEMBL30553000 0.72 PBRM1 (0.42) CYP1A2PBRM1TDP2GAAKDM4E
SCHEMBL2729079 0.72 PBRM1 (0.42) CYP1A2PBRM1TDP2GAAKDM4E
SCHEMBL23912881 0.67 TDP1 (0.35) TDP2NSD2ABL1PLCG1CES1
SCHEMBL15241059 0.67 AAK1 (0.50) AAK1ROCK2ROCK1
SCHEMBL15240550 0.66 ROCK2 (0.46) CYP1A2CYP2C19HTTPTAFRKDM4E
SCHEMBL6669536 0.65 PBRM1 (0.46) CYP1A2CYP2C19PBRM1SMN1; SMN2MEN1
SCHEMBL20202891 0.62 CYP1A2 (0.37) CYP1A2CYP2C19HTTALDH1A1RAB9A
SCHEMBL21781053 0.62 KDM4E (0.39) CYP1A2CYP2C19PBRM1KDM4EALDH1A1
SCHEMBL19688104 0.61 AHR (0.39) CYP1A2CYP2C19HTTPTAFRABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-8541572-B2 Compounds for the treatment of inflammatory disorders MERCK SHARP & DOHME CORP. (US) 2013-09-24 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS MERCK SHARP & DOHME CORP. 2012-01-12 US disclosed
WO-2010054279-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS SCHERING CORPORATION (US) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010181-A1 COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS TNF, ADAMTS1, ADAMTS7 TNF 1/4885CYP1A2 1067/4885CYP2C19 1601/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.